HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Oruka Therapeutics (NASDAQ: ORKA) and maintained a price target of $120 for the stock.